Aurora Cannabis Launches First Domestically Grown Medical Cannabis Brand in Germany Under New Cultivation License
Aurora Cannabis (NASDAQ: ACB) has launched IndiMed, its first German-cultivated medical cannabis brand, manufactured at their EU-GMP facility in Leuna, Germany. This development follows Germany's recent cannabis decriminalization and positions Aurora as one of only three licensed cultivators in the country.
The initial product release is Island Sweet Skunk, a dried flower sativa variant containing 20% THC and <1% CBD, scheduled for availability on January 27. The product is cultivated under GACP and EU-GMP guidelines, featuring hand-harvested flowers that undergo controlled drying and laboratory testing for purity and potency.
As the world's largest medical cannabis company in legal markets, Aurora's expansion in Germany demonstrates its commitment to serving the country's growing patient base with locally produced, high-quality medical cannabis products.
Aurora Cannabis (NASDAQ: ACB) ha lanciato IndiMed, il suo primo marchio di cannabis medica coltivato in Germania, prodotto nella loro struttura EU-GMP a Leuna, in Germania. Questo sviluppo arriva dopo la recente depenalizzazione della cannabis in Germania e posiziona Aurora come uno dei soli tre coltivatori autorizzati nel paese.
Il primo prodotto lanciato è Island Sweet Skunk, una variante sativa di fiore essiccato contenente il 20% di THC e meno dell'1% di CBD, previsto per la disponibilità il 27 gennaio. Il prodotto è coltivato secondo le linee guida GACP e EU-GMP, con fiori raccolti a mano che subiscono un'essiccazione controllata e test di laboratorio per purezza e potenza.
Essendo la più grande azienda di cannabis medica nei mercati legali, l'espansione di Aurora in Germania dimostra il suo impegno a servire la crescente base di pazienti del paese con prodotti di cannabis medica di alta qualità, prodotti localmente.
Aurora Cannabis (NASDAQ: ACB) ha lanzado IndiMed, su primera marca de cannabis medicinal cultivada en Alemania, fabricada en su instalación EU-GMP en Leuna, Alemania. Este desarrollo sigue a la reciente despenalización de la cannabis en Alemania y posiciona a Aurora como uno de solo tres cultivadores autorizados en el país.
El lanzamiento inicial de producto es Island Sweet Skunk, una variante sativa de flor seca que contiene un 20% de THC y menos del 1% de CBD, programado para estar disponible el 27 de enero. El producto se cultiva bajo las directrices de GACP y EU-GMP, presentando flores cosechadas a mano que se someten a un secado controlado y pruebas de laboratorio para pureza y potencia.
Siendo la empresa de cannabis medicinal más grande en mercados legales, la expansión de Aurora en Alemania demuestra su compromiso de atender a la creciente base de pacientes del país con productos de cannabis medicinal de alta calidad, producidos localmente.
오로라 캔나비스 (NASDAQ: ACB)가 독일에서 재배된 처음의 의료용 대마초 브랜드 IndiMed를 출시했습니다. 이 브랜드는 독일 루나에 위치한 EU-GMP 시설에서 제조됩니다. 이번 개발은 독일의 최근 대마초 비범죄화에 따른 것이며, 오로라는 해당 국가에서 허가된 세 개의 재배자 중 하나로 자리 잡았습니다.
초기 출시 제품은 Island Sweet Skunk로, 20% THC와 1% 미만의 CBD를 포함한 건조 꽃의 사티바 품종입니다. 이 제품은 1월 27일에 출시될 예정이며, GACP 및 EU-GMP 가이드라인에 따라 재배되며, 수확된 꽃은 손으로 수확되어 통제된 건조 과정을 거치고 순도와 효능을 위해 실험실 테스트를 받습니다.
법적 시장에서 세계 최대의 의료용 대마초 회사인 오로라의 독일에서의 확장은 고품질의 현지 생산 의료용 대마초 제품으로 증가하는 환자 기반에 서비스를 제공하겠다는 회사의 약속을 나타냅니다.
Aurora Cannabis (NASDAQ: ACB) a lancé IndiMed, sa première marque de cannabis médical cultivée en Allemagne, fabriquée dans son installation EU-GMP à Leuna, en Allemagne. Ce développement fait suite à la récente dépénalisation du cannabis en Allemagne et positionne Aurora comme l'un des seulement trois cultivateurs autorisés dans le pays.
La première sortie de produit est Island Sweet Skunk, une variété sativa de fleurs séchées contenant 20 % de THC et moins de 1 % de CBD, prévue pour être disponible le 27 janvier. Le produit est cultivé selon les directives GACP et EU-GMP, présentant des fleurs récoltées à la main qui subissent un séchage contrôlé et des tests de laboratoire pour la pureté et la puissance.
En tant que plus grande entreprise de cannabis médical sur les marchés légaux, l'expansion d'Aurora en Allemagne démontre son engagement à servir la base de patients croissante du pays avec des produits de cannabis médical de haute qualité, produits localement.
Aurora Cannabis (NASDAQ: ACB) hat IndiMed eingeführt, seine erste in Deutschland kultivierte medizinische Cannabis-Marke, die in seiner EU-GMP-Anlage in Leuna, Deutschland, hergestellt wird. Diese Entwicklung folgt auf die jüngste Entkriminalisierung von Cannabis in Deutschland und positioniert Aurora als einen von nur drei lizenzierten Züchtern im Land.
Die erste Produkteinführung ist Island Sweet Skunk, eine getrocknete Sativa-Variante mit 20% THC und weniger als 1% CBD, die ab dem 27. Januar verfügbar sein soll. Das Produkt wird gemäß den GACP- und EU-GMP-Richtlinien kultiviert, wobei die von Hand geernteten Blüten einer kontrollierten Trocknung und Laboruntersuchung auf Reinheit und Potenz unterzogen werden.
Als das größte Unternehmen für medizinisches Cannabis in legalen Märkten zeigt Auroras Expansion in Deutschland sein Engagement, der wachsenden Patientenbasis des Landes mit lokal produzierten, hochwertigen medizinischen Cannabisprodukten zu dienen.
- One of only three licensed cultivators in Germany
- Launch of first domestically produced medical cannabis product in Germany
- EU-GMP certified manufacturing facility in Leuna operational
- None.
Insights
The launch of IndiMed marks a pivotal milestone in Aurora's European strategy, particularly significant given Germany's position as Europe's largest medical cannabis market, valued at approximately
The EU-GMP facility in Leuna represents a strategic asset that differentiates Aurora in several key aspects:
- Local cultivation eliminates import duties and reduces transportation costs, potentially improving gross margins by
15-20% - Shorter supply chain enables faster market response and better inventory management
- Domestic production aligns with German healthcare preferences for locally manufactured pharmaceuticals
- EU-GMP certification facilitates potential distribution to other European markets
The initial product launch focusing on high-THC (
However, investors should note that while this development strengthens Aurora's competitive position, the immediate financial impact may be modest given the company's current market cap of
The timing of this launch, coinciding with Germany's cannabis policy liberalization, positions Aurora advantageously for potential market expansion. The infrastructure and regulatory compliance frameworks established for medical cannabis could provide a foundation for future adult-use market participation, should Germany proceed with broader legalization reforms.
NASDAQ | TSX: ACB
Investment in the region continues with the launch of IndiMed, the company's first locally grown brand in
"Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since
The premium product launching from the IndiMed brand is Island Sweet Skunk, dried flower, sativa,
Aurora leads the global medical cannabis industry with unmatched expertise, driving innovation and progress. Its steadfast commitment to growth in the dynamic German market cements its position as the industry's unrivaled leader.
Aurora's expertise in navigating complex European regulatory frameworks and manufacturing high-quality medical cannabis positions the company as the preferred leader to drive progress in the German market with confidence. By continually setting new global benchmarks, Aurora reinforces its status as the world's largest medical cannabis company operating in nationally legal markets.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's first German-cultivated medical cannabis product under the brand IndiMed, the timing for availability of that product in the German market, the Company's market leadership and status as the world's largest medical cannabis company operating in nationally legal markets, and the Company's ability to drive progress in the German market.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-launches-first-domestically-grown-medical-cannabis-brand-in-germany-under-new-cultivation-license-302357848.html
SOURCE Aurora Cannabis Inc.
FAQ
When will Aurora Cannabis (ACB) launch IndiMed in Germany?
What is the THC content of Aurora's new IndiMed Island Sweet Skunk product?
How many companies are licensed to cultivate cannabis in Germany alongside Aurora (ACB)?
What quality standards does Aurora's IndiMed follow in Germany?
